Despite Data Concerns, Panel Recommends First-In-Class Toe Implant
This article was originally published in The Gray Sheet
Cartiva, a toe implant to treat osteoarthritis, received a strong recommendation from a panel of FDA experts despite suggestions that the device had not fully proven itself.
You may also be interested in...
An FDA advisory panel recommended approval of Link Orthopedics' STAR ankle replacement system April 24 despite FDA reviewers' conclusion that results of the firm's pivotal trial are unclear
Bills to narrow the Medicare price negotiation program’s reach generated extensive discussion at the hearing.
The FDA commissioner also does not want the agency setting goals for rare disease treatment development.